Ruxolitinib

Abstract

Tuberculosis lymphadenitis: case reportIn a study of 170 patients with thalassemia, a man [age not stated] was described, who developed tuberculosis lymphadenitis during treatment with ruxolitinib for primary myelofbrosis with compound heterozygous Hb E-β 0 -thalassemia disease and Hb Pakse (PS).The man, who had had JAK2V617F mutation was diagnosed with primary myelofbrosis with compound heterozygous Hb Eβ 0 -thalassemia disease and Hb PS, received oral ruxolitinib (JAK2 inhibitor) 20mg twice daily. Subsequently, ruxolitinib showed significant clinical improvement. Also, 50% spleen size reduction was observed after 6 months of treatment. However, after one year of treatment, he developed tuberculosis lymphadenitis because of off-target effect of ruxolitinib on immune system.The man received unspecified first-line anti-TB agents and tuberculous lymphadenitis was successfully improved.